Biogen Inc

Pharmaceuticals
BIIB
$ 193 (1.5)%
Share price
$ 28 bn
Market Cap
$ 32 bn
Enterprise Value

Carbon footprint

1.8 Ton
GHG emissions per $ 1 mln investment
0.06x the weighted average for S&P 500
FY2020
How is this calculated?
-15%
YOY change in GHG emissions
Stronger than the -8.7% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-4%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

Biogen Inc aims to reduce Scope 1 + 2 by 55% by 2032 from a base year 2019


1.5°C
Biogen Inc's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Biogen Inc's GHG emissions (market-based) (Kt of CO2e)
Biogen Inc's Carbon intensity (Tons per 1 USDm)

Biogen Inc's carbon footprint

Biogen Inc reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 58 Kt (-9.8 /-14.5% y-o-y). Also positively, carbon intensity dropped to 4.3 t (-0.4 /-8.5% y-o-y).

Biogen Inc's Scope 3 emissions declined to 349 Kt (-76 /-17.8% y-o-y). This is a higher rate of decline than over the period since 4Q'17 (-7.8% CAGR).

The company is committed to reducing Scope 1 + 2 by 55% by 2032 from a base year 2019, which translates into the estimated reduction of -2.3 Kt per annum over the period of FY2021 - FY2032. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Company environmental metrics

Show more...